Source:http://linkedlifedata.com/resource/pubmed/id/11803223
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2002-1-22
|
pubmed:abstractText |
Our purpose was to compare the efficacy of 25 microg and 50 microg intravaginally administered misoprostol tablets for cervical ripening and labor induction. Either 25-microg (n: 58) or 50-microg (n: 56) misoprostol tablets were randomly administered intravaginally to 114 subjects with an unripe cervix for labor induction. The physician was blinded to the medication. Intravaginal misoprostol was given every 4 h until the onset of labor. The mean Bishop score before misoprostol administration was 2.1 +/- 1.6 in the 25-microg group and 2.0 +/- 1.4 in the 50-microg group (p > 0.05). With the 25-microg dose the time until delivery was significantly longer (991.2 +/- 514.4 min vs. 703.12 +/- 432.6 min in the 50-microg group). The use of oxytocin augmentation was significantly higher in the 25-microg group (63.8%) than the 50-microg group (32.1%; p < 0.05). The proportions of patients with tachysystoles and hypersystoles were not significantly different between the two groups (19 and 6.9%, respectively, in the 25-microg group and 25 and 17.8%, respectively, in 50-microg group; p > 0.05). Overall, in the 25-microg group more women achieved vaginal delivery (79.3 vs. 60.7%; p < 0.05). The rate of cesarean sections due to non-reassuring fetal status was higher in the 50-microg misoprostol group (28.6 vs. 10.3%; p < 0.05). The number of neonates with a low 1-min Apgar score (<7) was significantly higher in the 50-microg misoprostol group (26.8 vs. 8.6%; p < 0.05), but 5-min Apgar scores and umbilical artery blood gas values at the time of delivery were not significantly different between the groups (p > 0.05). One patient in the 25-microg group suffered a ruptured uterus. Intravaginal administration of 25 microg of misoprostol is a clinically effective labor induction regimen and has the least adverse effects and complications.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0378-7346
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2002 S. Karger AG, Basel
|
pubmed:issnType |
Print
|
pubmed:volume |
53
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
16-21
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11803223-Administration, Intravaginal,
pubmed-meshheading:11803223-Cervical Ripening,
pubmed-meshheading:11803223-Drug Administration Schedule,
pubmed-meshheading:11803223-Female,
pubmed-meshheading:11803223-Humans,
pubmed-meshheading:11803223-Labor, Induced,
pubmed-meshheading:11803223-Misoprostol,
pubmed-meshheading:11803223-Oxytocics,
pubmed-meshheading:11803223-Pregnancy,
pubmed-meshheading:11803223-Pregnancy Outcome,
pubmed-meshheading:11803223-Tablets
|
pubmed:year |
2002
|
pubmed:articleTitle |
Comparison of 25 and 50 microg vaginally administered misoprostol for preinduction of cervical ripening and labor induction.
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Istanbul, Turkey.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|